The National Institutes of Health (NIH) is launching a Phase 3 clinical trial to determine the efficacy of tecovirimat — the smallpox antiviral better known as TPOXX — for use in treating monkeypox as current data on its effectiveness against the virus is limited. The National Institute of Allergy and Infectious Diseases (NIAID) is sponsoring the trial, which is being led by the organization's AIDS Clinical Trials Group. The study is currently enrolling adults and children who have been infected with monkeypox in the U.S. TPOXX was approved by the Food and Drug Administration (FDA) in 2018 to treat smallpox. It was authorized for use in treating monkeypox in August based on studies tr
Hence then, the article about nih launches clinical trial evaluating efficacy of tpoxx against monkeypox was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( NIH launches clinical trial evaluating efficacy of TPOXX against monkeypox )